Merck & Co., Inc.: PharmaVitae Profile

Introduction

This analysis examines the historical and forecast performance for Merck & Co. in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.
Features and benefits

* Gain insight into Merck & Co.'s strategic outlook across the next 6 years* Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source
Highlights

Strategic insight into the prospects for Merck & Co. over the next six years. Picking out key strengths, weaknesses, opportunities and threats and evaluating the company's prescription pharmaceuticals outlook using a variety of cuts of the historical and forecast sales.
Your key questions answered

* Benchmark Merck & Co.'s performance against key rivals in the prescription pharmaceutical sector.* Assess the continued commercial and strategic impact of Merck & Co.'s 2009 acquisition of Schering-Plough.* Key drivers from Merck’s newly expanded marketed and launch portfolios including Januvia, Isentress, Saphris and Simponi.

[Studien Infos ausblenden]

TABLE OF CONTENTS
ABOUT DATAMONITOR HEALTHCARE 2
About the PharmaVitae team 2
Chapter 1 About this profile 3
PharmaVitae Explorer database 3
Chapter structure 3
Data sourcing 4
Chapter 2 Executive summary 5
Key findings 5
Prescription pharmaceutical sales and growth rate performance, 2003–15 6
Financial performance, 2003–15 7
Merck & Co.: PharmaVitae forecasts at a glance 8
Strategic insight 9
SWOT analysis 16
Chapter 3 Quarterly news update 23
Latest quarterly sales 23
Latest quarterly financial analysis 25
Latest comment 26
Latest prescription pharma product news 32
Latest corporate news 36
Future product milestones 38
Chapter 4 Company introduction 39
Key findings 39
Background 40
Key corporate developments 40
Chapter 5 Company sales 46
Key findings 46
Prescription pharmaceutical sales and growth rate analysis, 2003–15 47
Product analysis 49
Therapy area analysis 57
Geographic analysis 59
Launch/core/expiry analysis 61
Molecule type analysis 68
Externalization analysis 70
Chapter 6 Company financials 72
Key findings 72
Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2003–09 73
Operating costs and profit analysis 74
Chapter 7 Key products 79
Overview 79
Chapter 8 Appendix 112
References 112
Abbreviations 112
Exchange rates 114
About Datamonitor 115
Datamonitor consulting 115
Disclaimer 117


TABLE OF TABLES
Table 1: Merck & Co. – PharmaVitae forecasts at a glance 8
Table 2: Big Pharma peer set ranked by 2008 prescription pharmaceutical sales 9
Table 3: Big Pharma peer set sales forecasts($m), 2009–15 10
Table 4: New Merck’s launching pipeline 11
Table 5: Merck & Co. quarterly sales ($m), Q309-Q310 23
Table 6: Merck & Co. quarterly financials ($m), Q309-Q310 25
Table 7: Merck & Co. future product milestones, 2010–12 38
Table 8: Merck & Co. product portfolio overview ($m), 2003–09 50
Table 9: Merck & Co. product portfolio overview ($m), 2009–15 53
Table 10: Merck & Co. prescription pharmaceutical sales by therapy area ($m), 2009–15 58
Table 11: Merck & Co. prescription pharmaceutical sales by geographic region ($m), 2009–15 60
Table 12: Merck & Co. launch portfolio overview ($m), 2009–15 62
Table 13: Merck & Co. core portfolio overview ($m), 2009–15 64
Table 14: Merck & Co. expiry portfolio overview ($m), 2009–15 65
Table 15: Merck & Co. prescription pharmaceutical sales by molecule type ($m), 2009–15 69
Table 16: Merck & Co. prescription pharmaceutical sales by source ($m), 2009–15 71
Table 17: Total Merck & Co. sales by business unit ($m), 2003–09 73
Table 18: Merck & Co. operating revenue/cost analysis ($m), 2003–09 75
Table 19: Merck & Co. operating cost ratio analysis (% of total revenues), 2003–09 76
Table 20: Merck & Co. operating cost ratio analysis (% of total revenues), 2009–15 77
Table 21: Merck & Co. operating revenue/cost analysis ($m), 2009–15 78
Table 22: Merck & Co. key products overview 79
Table 23: Januvia: overview 81
Table 24: Janumet: overview 82
Table 25: sitagliptin/pioglitazone: overview 83
Table 26: Januvia: sales forecast ($m), 2009–15 84
Table 27: Janumet: sales forecast ($m), 2009–15 84
Table 28: sitagliptin/pioglitazone: sales forecast ($m), 2009–15 85
Table 29: Total sitagliptin franchise: sales forecast ($m), 2009–15 85
Table 30: Remicade: overview 87
Table 31: Simponi: overview 88
Table 32: Remicade: sales forecast ($m), 2009–15 89
Table 33: Simponi: sales forecast ($m), 2009–15 89
Table 34: Isentress: overview 91
Table 35: Isentress: sales forecast ($m), 2009–15 92
Table 36: ProQuad/MMRII/Varivax: overview 94
Table 37: ProQuad/MMRII/Varivax: sales forecast ($m), 2009–15 95
Table 38: Singulair: overview 97
Table 39: Singulair: sales forecast ($m), 2009–15 98
Table 40: Zetia: overview 100
Table 41: Vytorin: overview 101
Table 42: Zetia: sales forecast ($m), 2009–15 102
Table 43: Vytorin: sales forecast ($m), 2009–15 102
Table 44: Saphris: overview 104
Table 45: Saphris: sales forecast ($m), 2009–15 105
Table 46: Cozaar/Hyzaar: overview 107
Table 47: Cozaar/Hyzaar: sales forecast ($m), 2009–15 108
Table 48: SCH 530348: overview 110
Table 49: SCH 530348: sales forecast ($m), 2009–15 111
Table 50: Exchange rates, 2010 114


TABLE OF FIGURES
Figure 1: The PharmaVitae Explorer 3
Figure 2: Merck & Co. prescription pharmaceutical performance, sales ($m) and growth rate (%), 2003–15 6
Figure 3: Merck & Co.’s financial performance ($m), 2003–15 7
Figure 4: Merck & Co. launch product sales ($m), 2009–15 12
Figure 5: Merck & Co. launch/core/expiry configuration ($m), 2009–15 13
Figure 6: Merck & Co. prescription pharmaceutical sales by therapy area (% total), 2003–15 14
Figure 7: Merck & Co. prescription pharmaceutical sales by geography (% total), 2003–15 15
Figure 8: Merck & Co. SWOT analysis 16
Figure 9: Merck & Co. prescription pharmaceutical performance, sales ($m) and growth rate (%), 2003–15 47
Figure 10: Merck & Co. Key product sales ($m), 2003–15 49
Figure 11: Merck & Co. key sales growth drivers and resistors ($m), 2003–09 52
Figure 12: Merck & Co. key sales growth drivers and resistors ($m), 2009–15 55
Figure 13: Merck & Co. prescription pharmaceutical sales by therapy area ($m), 2003–15 57
Figure 14: Merck & Co. prescription pharmaceutical sales by geographic region ($m), 2003–15 59
Figure 15: Merck & Co. launch/core/expiry configuration ($m), 2009–15 67
Figure 16: Merck & Co. prescription pharmaceutical sales by molecule type ($m), 2003–15 68
Figure 17: Merck & Co. prescription pharmaceutical sales by source ($m), 2003-15 70
Figure 18: Merck & Co. operating revenue/cost analysis ($m), 2003–15 74


[Inhaltsverzeichnis ausblenden]